このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study (NAPOLI)

2026年8月30日 更新者:Ferrucci Massimo、Istituto Oncologico Veneto IRCCS

NAPOLI: Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study

The NAPOLI Study is a retrospective multicenter observational study designed to characterize hormone receptor-negative/low invasive lobular carcinoma of the breast. The study will collect real-world clinicopathological, molecular, therapeutic and outcome data from patients diagnosed and treated at participating centers. The aim is to describe the clinical behavior, pathological features, receptor profile, treatments received and oncologic outcomes of this rare breast cancer subtype.

調査の概要

詳細な説明

Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer (BC), accounting for approximately 10-15% of all invasive BCs. ILC is characterized by loss or dysfunction of the E-cadherin/catenin adhesion complex, typically due to CDH1 alterations, and by a distinctive discohesive and infiltrative growth pattern. These features translate into specific and unique biological, clinical and therapeutic challenges compared with invasive carcinoma of no-special type (IC-NST).

The majority of ILCs - up to 90% - are estrogen receptor (ER)-positive, progesterone receptor (PR)-positive and HER2-negative. In contrast, hormone receptor (HR)-negative ILC (ER and PR expression <1%), HR-low ILC (1-10% HR-positive cells), and HER2-positive (any HR expression) ILC are rare, biologically and clinically heterogeneous, and markedly underrepresented in clinical trials and large translational datasets. Moreover, the absence or very low expression of hormone receptors limits the role of endocrine therapy, thereby narrowing therapeutic options and potentially affecting prognosis. The efficacy of anti-HER2 therapies in ILC remains less defined than in IC-NST, due to the rarity of HER2 overexpression in breast cancer of lobular histotype (<10% of all ILC). Consequently, clinical outcomes and response to neoadjuvant therapies across both HR-positive/HER2-positive and HR-negative/HER2-positive represent an area where clinical data are lacking.

Recent genomic and transcriptomic studies have identified alterations involving pathways such as CDH1, ERBB2, TP53, PI3K/AKT/PTEN, and DNA damage response pathways, along with other potentially actionable molecular mechanisms. These findings suggest that HR-negative/low ILC may constitute a biologically distinct entity rather than simply an uncommon variant of conventional HR-positive lobular carcinoma, raising important questions regarding prognosis, optimal treatment sequencing, indications and response to neoadjuvant therapies, and the potential role of targeted and biomarker-driven treatments.

Triple-negative ILC (TN-ILC) is exceedingly rare, accounting for approximately 1-2% of all ILC and well below 1% of all invasive BCs, which largely explains their marked underrepresentation in prospective trials, and the consequent lack of disease-specific evidence to guide clinical management. Available evidence suggests that TN-ILC is not simply the lobular counterpart of conventional basal-like triple-negative BC. Indeed, when profiled by PAM50, the majority of TN-ILC are non-basal-like, in contrast to conventional TN IC-NST. Moreover, TN-ILC appears enriched for older age at diagnosis, pleomorphic and apocrine/histiocytoid morphology, androgen receptor (AR) expression, and luminal androgen receptor (LAR)-like biology. Importantly, TN-ILC has been reported to show poor responsiveness to conventional neoadjuvant chemotherapy despite aggressive clinical behavior, raising questions about the optimal systemic treatment strategy and the potential value of biomarker-driven approaches. The few dedicated series available consistently report an unfavorable course, with a pooled pathologic complete response (PCR) rate of approximately 22.5%: in the largest early-stage cohort described to date, 5- and 10-year invasive disease-free survival were only approximately 50% and 37%, respectively. In addition, potentially actionable ERBB2 mutations have been reported in up to ~20% of TN-ILC and, together with frequent enrichment in DNA-damage-response, recurrent ESRRA mutations and PI3K/AKT/PTEN pathway alterations, may represent tractable therapeutic vulnerabilities, including HER2 tyrosine-kinase inhibitors, PARP or PI3K/AKT inhibitors.

HER2-positive ILC represents another uncommon and clinically relevant subgroup. HER2 overexpression/amplification in ILC is more frequently observed in pleomorphic and high-grade variants, and may be associated with distinct clinicopathologic features, higher proliferative activity and worse prognosis than classic HR-positive/HER2-negative ILC. However, data specific to HER2-positive ILC remain sparse, and most recommendations are extrapolated from IC-NST cohorts. Whether patterns of response to anti-HER2 neoadjuvant therapy, rates of PCR, surgical outcomes and recurrence patterns differ from those observed in IC-NST remains insufficiently defined.

Apocrine differentiation in the lobular setting is of particular interest, as it represents a rare and potentially distinct phenotype, commonly associated with HR negativity, AR expression, HER2 pathway activation in a subset of cases, luminal androgen receptor (LAR) biology, and unique genomic alterations, thereby providing a biological rationale for AR-directed or other targeted therapeutic strategies. In the lobular setting, apocrine, pleomorphic and histiocytoid features may overlap morphologically and biologically. However, the true prevalence, genomic correlates, treatment patterns and outcomes of apocrine lobular tumors remain poorly characterized. In the ductal setting TN apocrine carcinomas have shown markedly low PCR rates to neoadjuvant chemotherapy (as low as ~7%, versus ~30% in non-apocrine TN BC), and LAR-subtype tumors achieve the lowest PCR across TN subtypes (~14% versus ~43%). As apocrine and LAR features are enriched in HR-negative/low ILC, comparably low chemosensitivity is expected in this setting, further supporting a dedicated, biomarker-driven therapeutic approach.

Because of the rarity of these subtypes, prospective randomized studies are unlikely to be carried out in the near future. A large international real-world cohort is therefore needed to clarify whether HR-negative/low ILC, apocrine/LAR-enriched lobular tumors and HER2-positive ILC represent clinically meaningful and biologically distinct entities, and to identify potential prognostic and predictive biomarkers.

The NAPOLI study is designed to assemble a large international cohort of patients with HR-negative/low and/or HER2-positive ILC, with a special focus on apocrine/LAR features, molecular alterations, imaging presentation, multidisciplinary treatment patterns, response to neoadjuvant therapies, surgical and axillary management, recurrence patterns, and oncologic outcomes. The overarching aim is to generate disease-specific evidence to improve risk stratification, identify clinically relevant prognostic and predictive biomarkers, guide multidisciplinary management (i.e. the use of neoadjuvant chemotherapy) and support future translational and biomarker-driven studies in this rare and underexplored subgroup of BC.

研究の種類

観察的

入学 (推定)

250

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

なし

サンプリング方法

非確率サンプル

調査対象母集団

Patients diagnosed between January 1, 2010 and December 31, 2025 will be included. Follow-up will be collected until the most recent available clinical update.

説明

Inclusion Criteria:

  • Female or male patients aged ≥18 years;
  • Histologically confirmed ILC, confirmed by E-cadherin loss/aberrant expression and/or p120 cytoplasmic relocalization and/or CDH1 alteration;
  • HR-negative (ER <1% and PR <1%) or HR-low (ER and/or PR 1-10%) disease, as defined by ASCO/CAP guidelines, is eligible regardless of HER2 status (assessed according to 2025 ASCO/CAP criteria, with HER2-low and HER2-ultralow status recorded where assessable);
  • HR-positive (ER>10% according to the ASCO/CAP guidelines) ILC is eligible only if HER2 status is positive;
  • Mixed ductal-lobular carcinomas are eligible provided that a clearly identified invasive lobular component is present and predominant (>50% lobular) and HR-negative/low criteria are met;
  • Stage I-III disease at diagnosis; Patients with de novo stage IV disease who underwent surgery of the primary tumor will not be included in the main study cohort but may be captured in a separate exploratory cohort for dedicated analysis;
  • Patients who underwent surgery of the primary tumor at the participating institution, either upfront or after neoadjuvant systemic treatment;
  • Diagnosis occurred between 1 January 2000 and 31 December 2025;
  • Minimum follow-up of 12 months for patients without an event, unless recurrence or death occurred earlier;
  • Local review by a dedicated breast pathologist to confirm the diagnosis and the related molecular features, with particular attention to the confirmation of apocrine morphology.

Exclusion Criteria:

  • Pure IC NST without any lobular invasive component;
  • ER or PR expression >10% in the invasive component, in cases with negative HER2 status;
  • In situ lobular neoplasia (lobular carcinoma in situ) without an invasive component;
  • De novo stage IV disease (such patients, if they underwent surgery of the primary tumor, will be captured in a separate exploratory cohort for a dedicated analysis)
  • Synchronous invasive BC of another dominant histology requiring systemic treatment that precludes attribution of outcomes to HR-negative/low ILC;
  • Prior invasive BC under active systemic treatment at the time of diagnosis, unless clearly documented as unrelated and not expected to confound outcomes;
  • Insufficient data or follow up

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
介入・治療
Triple-negative ILC
ER <1%, PR <1% and HER2-negative (IHC 0, 1+, or 2+ with negative ISH). Within this cohort, HER2 expression will be further categorized, where assessable, as HER2 null (IHC 0, no staining), HER2-ultralow (IHC 0+ with faint/incomplete staining in ≤10% of tumor cells) and HER2-low (IHC 1+, or 2+/ISH-negative).
Upfront Conservative or Demolitive Breast Surgery
Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
Adjuvant or Neoadjuvant Endocrine Therapy
Adjuvant or Neoadjuvant Chemotherapy
HER2-positive ILC
HER2-positive disease, defined as IHC 3+ or IHC 2+ ISH-positive. Subgroups within this cohort will include HR-negative ILC (ER and PR both <1%) and HR-positive (ER>10%) HER2-positive ILC.
Upfront Conservative or Demolitive Breast Surgery
Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
Adjuvant or Neoadjuvant Endocrine Therapy
Adjuvant or Neoadjuvant Chemotherapy
HR-low ILC (cross-cutting category)
ER and/or PR 1-10%, with neither receptor >10%, analyzed separately as a distinct group and also within the HER2-defined groups.
Upfront Conservative or Demolitive Breast Surgery
Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
Adjuvant or Neoadjuvant Endocrine Therapy
Adjuvant or Neoadjuvant Chemotherapy
Exploratory Subgroups (cross-cutting category)
Apocrine and/or LAR-featured ILC, and non-classic lobular variants (pleomorphic, histiocytoid and other rare histologic variants).
Upfront Conservative or Demolitive Breast Surgery
Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
Adjuvant or Neoadjuvant Endocrine Therapy
Adjuvant or Neoadjuvant Chemotherapy

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Invasive disease-free survival (iDFS)
時間枠:Through study completion, an average of 5 years
Time from definitive surgery to first invasive event (ipsilateral invasive, locoregional invasive, or distant recurrence, contralateral invasive BC)
Through study completion, an average of 5 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Overall survival (OS)
時間枠:Through study completion, an average of 5 years
Through study completion, an average of 5 years
Distant disease-free survival (DDFS)
時間枠:Through study completion, an average of 5 years
Through study completion, an average of 5 years
Breast cancer-specific survival (BCSS)
時間枠:Through study completion, an average of 5 years
Through study completion, an average of 5 years
Locoregional recurrence-free survival (LRRFS)
時間枠:Through study completion, an average of 5 years
Through study completion, an average of 5 years
Recurrence rate and patterns
時間枠:Through study completion, an average of 5 years
Local, regional, distant, contralateral, and site-specific distant (including ILC-enriched sites)
Through study completion, an average of 5 years

その他の成果指標

結果測定
メジャーの説明
時間枠
Pathologic complete response (pCR) - ypT0/Tis ypN0, with residual cancer burden (RCB) class distribution; in the neoadjuvant cohort, event-free survival (EFS) from treatment initiation where data permit
時間枠:Through study completion, an average of 5 years
Through study completion, an average of 5 years
Multidisciplinary treatment patterns and treatment-related outcomes according to therapeutic strategy (upfront surgery versus neoadjuvant treatment), surgical management (including reconstruction/oncoplastic approaches), systemic and radiation therapy
時間枠:Through study completion, an average of 5 years
Through study completion, an average of 5 years
Prognostic, predictive and potential therapeutic relevance of clinicopathologic, molecular, and biologic features
時間枠:Through study completion, an average of 5 years
Somatic and germline alterations, TME features (stromal TILs, PD-L1 status, immune-related biomarkers), apocrine differentiation, LAR phenotype, HER2 status, HR-negative versus HR-low status, and classic versus pleomorphic/non-classic ILC variants
Through study completion, an average of 5 years
Biomarker-outcome associations with iDFS, pCR and OS
時間枠:Through study completion, an average of 5 years
Through study completion, an average of 5 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディチェア:Francesco Milardi, MD、Veneto Institute of Oncology IRCCS

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

便利なリンク

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年5月1日

一次修了 (推定)

2027年5月1日

研究の完了 (推定)

2027年12月31日

試験登録日

最初に提出

2026年5月19日

QC基準を満たした最初の提出物

2026年5月23日

最初の投稿 (実際)

2026年5月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月2日

QC基準を満たした最後の更新が送信されました

2026年8月30日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する